| Company | Price | P/E | EPS | Marcap | 1 Yr performance | 52W Low - High | 52W Low - High range | Valuation |
|---|---|---|---|---|---|---|---|---|
| argenx SE | € 424.00 | 614.49 | 0.69 | 21,794 | 13.22 % | 320.10 - 491.80 | Overvalued | |
| Biomarin Pharmaceutical Inc. | $ 92.94 | 41.31 | 2.25 | 16,984 | -10.97 % | 76.22 - 117.27 | In Value | |
| Galapagos NV | € 36.48 | 280.62 | 0.13 | 2,390 | 1.62 % | 30.37 - 44.03 | Overvalued | |
| Incyte Corporation | $ 54.70 | 12.05 | 4.54 | 12,030 | -34.97 % | 52.16 - 86.01 | Undervalued | |
| Moderna, Inc. | $ 80.32 | 2.12 | 37.93 | 32,251 | -56.51 % | 69.51 - 210.04 | Undervalued | |
| MorphoSys AG | € 24.79 | -6.23 | -3.98 | 812 | 52.37 % | 12.05 - 31.56 | Overvalued | |
| Nicox S.A. | € 0.49 | -0.60 | -0.82 | 18 | -60.48 % | 0.49 - 1.22 | Undervalued | |
| Pharming Group N.V. | € 1.07 | 107.00 | 0.01 | 684 | -4.46 % | 0.92 - 1.38 | Overvalued |